Epidiolex cannabidiol: Phase III started

GW began a double-blind, placebo-controlled, international Phase III trial to evaluate 25 and 50 mg/kg/day oral Epidiolex

Read the full 178 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE